Industry, Cancer Groups Draft Blueprint For PD-1 Companion Dx Approvals
This article was originally published in The Gray Sheet
Executive Summary
Drug and test firms want to standardize FDA's companion diagnostic assessments for the high-profile new class of PD-1/PD-LI immunotherapy cancer drugs. A draft blueprint for addressing the issue was discussed at a March 24 meeting convened by FDA and several cancer research organizations.